Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Ipca

    Jump to

    • Why IPCA-Unichem is not such a bad deal

    • IPCA Labs: Strong revival for domestic formulations

    • IPCA Q4 PAT seen up 126.5% YoY to Rs. 194.8 cr: Sharekhan

    • Pharma: Ignore the noise as the core allocation is incremental

    • FIPB clears 10 FDI proposals worth Rs 2,858 crore

    • Cadila up 5%, Credit Suisse bullish on strong US pipeline

    • Nifty ends below 8350; banks & pharma support, metals melt

    • Sensex, Nifty continue to gain; banks surge, metals fall

    • Cipla, Cadila Health, Natco Pharma top picks: AnandRathi

      AnandRathi has come out with its report on India healthcare. According to the research firm, EBITDA margins are expected to be stable at 22-23 percent during the quarter. "Cipla, Cadila Healthcare, Natco Pharma, and Unichem Laboratories are the top picks, says AnandRathi.

    • Nifty to hold 5800; maintain long positions: Sukhani

      Technical analyst, Sudarshan Sukhani, s2analytics.com is mildly bullish on the Nifty.

    • Bullish on Ipca Labs, says Gautam Chhaochharia

      The pharma story is similar both on the generic front as well as on local businesss so we like IPCA laboratories ays Gautam Chhaochharia, UBS India

    • Mkt to be choppy; traders close short positions: Sukhani

      Technical analyst, Sudarshan Sukhani, s2analytics.com says in the intermediate term the undercurrent for market is bearish.

    • Market heading to lower levels; target at 5500: Sukhani

      In an interview to CNBC-TV18 technical analyst, Sudarshan Sukhani of s2analytics.com shared his reading on market and stocks across various sectors.

    • Nifty to make new highs after taking out 6000: Baliga

      In an interview to CNBC-TV18, Independent Analyst, Ambareesh Baliga shared his reading and outlook on markets and specific stocks.

    • India strategy, top picks for December 2012: PLilladher

      Prabhudas Lilladher has come out with its report on "India strategy & top ideas". Infosys, ICICI Bank, Wipro, Cairn India, Power Grid Corporation, Dr.Reddy's Laboratories, Adani Port & SEZ and Ranbaxy Laboratories are the stocks from large cap space

    • Citi picks top pharma stocks; positive on Ranbaxy, Lupin

      In an interview with CNBC-TV18, Prashant Nair, Director & Deputy Head of Research, Citi India gives his outlook on the pharma sector. He picks Ranbaxy, Lupin, Apollo Hospital and Ipca as preferred stocks and believes, they will outperform not just the market but also its peers from the pharma space.

    • Buy Glenmark Pharma, Ipca Labs says Emkay

      Emkay Global Financial Services has come out with its report on pharma space. According to the research firm one can buy Glenmark and IPCA.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347